News & Insights

February 13, 2023 | Lowenstein Represents Corbus Pharmaceuticals in Exclusive Licensing Agreement to Develop Clinical Stage Antibody Drug Conjugate

Lowenstein Sandler represents Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a precision oncology company, in its exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited...

February 13, 2023 | World Trademark Review 1000 Again Includes Partners Vanessa A. Ignacio and Matthew P. Hintz Among World’s Leading Trademark Professionals

Lowenstein Sandler and two of its trademark partners, Vanessa A. Ignacio and Matthew P. Hintz, are included in the 2023 edition of World Trademark Review 1000 – The World’s Leading Trademark Professionals (WTR 1000). This is the twelfth consecutiv...

February 10, 2023 | Lowenstein Represents Sales Agents in ATM Agreement to Issue $100M Common Stock in Meta Materials

Lowenstein Sandler represented Ladenburg Thalmann & Co. Inc., B. Riley Securities, Inc. and Roth Capital Partners, LLC in an At-The-Market sales agreement for the issuance of up to $100 million of common stock of Meta Materials Inc. (NASDAQ:MM...

SEE MORE >